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Background: Few studies have compared the prognosis and liver-related mortality in patients with NAFLD (nonalcoholic
fatty liver disease) and AFLD (alcoholic fatty liver disease). We aimed to investigate the etiology and liver-related mortality
of patients with liver biopsy verified fatty liver disease in a population based setting.
Methods: In this retrospective study, all patients who underwent a liver biopsy 1984–2009 at the National University
Hospital of Iceland were identified through a computerized pathological database with the code for fatty liver. Only
patients with NAFLD and AFLD were included and medical records reviewed. The patients were linked to the Hospital
Discharge Register, the Causes of Death Registry and Centre for Addiction Medicine.
Results: A total of 151 had NAFLD and 94 AFLD with median survival of 24 years and 20 years, respectively (p = NS). A
total of 10/151 (7%) patients developed cirrhosis in the NAFLD group and 19/94 (20%) in AFLD group (p = 0.03). The
most common cause of death in the NAFLD group was cardiovascular disease (48%). Liver disease was the most
common cause of death in the AFLD group (36%), whereas liver-related death occurred in 7% of the NAFLD group.
The mean liver-related death rate among the general population during the study period was 0.1% of all deaths. There
was a significantly worse survival for patients in the AFLD group compared to the NAFLD group after adjusting for
gender, calendar year of diagnosis and age at diagnosis (HR 2.16, p = 0.009). The survival for patients with moderate to
severe fibrosis was significantly worse than for patients with mild fibrosis after adjusting for gender, calendar year of
diagnosis and age at diagnosis (HR 2.09, p = 0.01).
Conclusions: Patients with fatty liver disease showed a markedly higher risk of developing liver-related death
compared to the general population. The AFLD group had higher liver-related mortality and had a worse survival than
the NAFLD group. Patients with more severe fibrosis at baseline showed a worse survival than patients with none or
mild fibrosis at baseline.
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Fatty liver disease is clinically categorized into two main
groups, alcoholic fatty liver disease (AFLD) and non-
alcoholic fatty liver disease (NAFLD). NAFLD is becoming
one of the most common liver diseases worldwide [1] with
a prevalence up to 30% in the general population [2] and* Correspondence: einarsb@landspitali.is
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article, unless otherwise stated.it can progress to end-stage liver disease [3]. NAFLD is as-
sociated with insulin resistance, and has been considered
to be the hepatic component of the metabolic syndrome
[3-5]. Patients with NAFLD have been shown to have in-
creased cardiovascular mortality compared to the general
population [6,7]. Only a few studies have assessed the
prognosis and risk of liver-related death in patients with
biopsy verified NAFLD in a population based setting [6,7].
Thus, even though NAFLD is potentially a serious condi-
tion well designed population based studies on its natural
history are lacking. Most recent studies on fatty liverntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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portant cause of fatty liver and only a few studies have
compared the long term prognosis between NAFLD and
AFLD [8-10].
The aims of this study were 1) to examine the natural
history and outcome of patients with fatty liver disease
with non-alcoholic and alcoholic etiologies. 2) Compare
the prognosis and liver-related mortality in patients with
NAFLD and AFLD, and compare these patients to the
liver-related mortality in the general population. Our hy-
pothesis was that these patients suffer from increased liver-
related morbidity compared to the general population.
Methods
Population and case finding
In this retrospective study, a search was undertaken in a
computerized diagnoses database from 1984 (when the
pathology registry commenced their electronic registra-
tion) to 2009, in the Department of Pathology at the
National University Hospital (NUH) of Iceland and identi-
fied all liver biopsies analysed and registrated in the
SNOMED coding-system, T-56000 and the M-50080 as
having fatty change. The SNOMED (Systemized Nomen-
clature of Medicine) is a coding system used in the
pathology laboratories in Iceland to specify: Procedure,
Topography, Morphology, Disease and Etiology. This is a
very valuable coding system for retrieving data and
pathology reports from past years, like biopsies of the liver
(T-56…) showing fatty change (M-50080).
The catchment area of the NUH covers >95% of the
population in Iceland.
All medical records from these patients were exam-
ined with respect to the following exclusion criteria: 1)
presence of acute or chronic liver disease: PBC,
autoimmune hepatitis, alfa-1-antitrypsin deficiency,
hemochromatosis and viral hepatitis. 2) jejunoileal by-
pass operation. 3) use of drugs known to be associated
with fatty liver disease such as methotrexate, amioda-
rone, tamoxifen and high doses of corticosteroids. 4)
malignancy at the time of index liver biopsy. 5) age
under eighteen years at the time of index liver biopsy.
6) gallstone surgery at the time of index liver biopsy.
The patients with gallstone surgery at the time of index
liver biopsy were excluded to better represent the pa-
tients who would undergo a liver biopsy in clinical
practice and not just the incidental finding of fatty liver
during an operation.
Indications for the index biopsy in the cohort were el-
evated liver tests, mainly serum alanine aminotransferase
(ALT) and serum aspartate aminotransferase (AST) and/
or hepatomegaly or suspected alcoholic liver disease. A
total of 420 patients met the inclusion criteria and were
divided into two groups, non-alcoholic and alcoholic
group respectively (Figure 1).Data collection
The following information was obtained from the medical
records and recorded at baseline: gender, age at diagnosis,
height, weight and body mass index (BMI), history of
diabetes mellitus, hyperlipidemia, hypertension, cardio-
and cerebrovascular disease, liver disease and malignancy.
Data on drug and alcohol intake was noted in the medical
records. Patient with a reported alcohol problem or abuse
or an alcohol-related diagnosis before or at the time of
liver index biopsy were considered to have alcoholic fatty
liver disease. The diagnosis of cirrhosis was accepted in
patients who had a discharge diagnosis, a death certificate
diagnosis and/or histological confirmation in the follow-
up period indicating cirrhosis. Laboratory data included at
baseline were: AST, ALT, bilirubin, albumin, alkaline
phosphatase (ALP), prothrombin time (PT), glucose,
platelets count (PLT), serum cholesterol, serum triglycer-
ides (TG) and mean corpuscular volume (MCV). The last
follow-up date was the 30th of November 2011.
Follow-up
All members of the cohort were linked through their
unique personal identification number to the centralized
Hospital Discharge Register at the Directorate of Health
and the Registry of Causes of Death (RCD) at Statistics
Iceland. Information was obtained from National Centre
of Addiction Medicine in Iceland on whether or not the
patients had undergone addiction therapy before or after
the time of the index liver biopsy. This information was
obtained from the addiction centre without knowledge
of the liver biopsy results.
Patients were excluded if they were lost to follow-up
in the registries. 8 patients were lost to follow-up.
Ethical considerations
The study was approved by the National Bioethics Com-
mittee (10-029-V1-S1) and the Icelandic Data Protection
Authority (S4766/2010).
Histological classification
The index liver biopsies were formalin fixed and treated
routinely in the pathology laboratory. They were paraffin
embedded and cut in 4–5 micrometer thick sections. The
sections were stained with hematoxylin and eosin, periodic
acid Schiff reagent (PAS) with diastase and for reticulin. In
addition a connective tissue stain, Weigert van Gieson or
most commonly Masson Trichrome stain was performed.
All histological slides were reviewed by experienced pathol-
ogists without knowledge of the clinical or biochemical
data of the patients. Three pathologists (Jon G. Jonasson,
David E. Kleiner and Sylvia O. Einarsdottir) divided the
slides between them and reviewed all of the samples over a
period of 2 years. The assessment was blinded to the
clinical details. Second review to examine inter-observer
All liver biopsies during the period 1984-
2009 with a histological diagnosis of 
fatty liver
(n=420)
Eligible patients
(n=245) 58%
Excluded patients
(n=175) 42%
Non-alcoholic 
group
(n=151) 66%
Alcoholic group
(n=94) 34%
Gallstones n=17
Drugs n=19
Hepatic disease n=36
Malignancy n=59
Other medical diseases n=14
Jejunoileal bypass operation n=2
Un- or misclassified samples n=10
Lost or missing samples n=10
Lost to follow-up n=8
Figure 1 Flowchart of the patients. Reasons for exclusion from the study are shown.
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were recorded in a semi-quantitative manner regarding
steatosis and fibrosis, which was initially proposed by
Brunt et al. in 1999 and developed further by Kleiner et al.
[11,12]. Grade 0 steatosis was defined as < 5% fat and thus
not compatible with fatty liver disease. Fibrosis stage were
defined as follow: 0: none. 1: Perisinusoidal or periportal
fibrosis. 1A: mild, zone 3, perisinusoidal. 1B: Moderate,
zone 3, perisinusoidal. 1C: Portal/periportal. 2: Perisinu-
soidal, portal/periportal. 3: Bridging fibrosis. 4: Cirrhosis.Statistical analysis
Statistical testing was performed using R-software. The re-
sults were presented as medians, interquartile range and
range and as number (%). The Mann–Whitney U-test was
used to test for differences between groups. Dichotomous
variables were compared by using the Chi-square (X2) or
Fischer’s exact test. A p-value of less than 0.05 was consid-
ered statistically significant. The survival curves were
estimated by the Kaplan-Meier estimator, using years as
the time-scale and taking delayed entry into account.
Differences between groups were investigated by Wald test
in Cox proportional hazards model, with age as the time-
scale, adjusting for gender, calendar year of diagnosis and
age of diagnosis. The primary end-point was death from all
causes.Results
Overall 2262 liver biopsies were performed at the
University Hospital of Iceland during the study period. A
total of 420 patients with at least one index biopsy were
identified by the computerized search in the pathology
database as having fatty liver on biopsy. Those who were
misclassified and did not have fatty liver on review were ex-
cluded (Figure 1). A total of 175 patients were excluded for
other reasons than based on histopathology (Figure 1). The
remaining study group of 245 patients had no signs of viral
hepatitis in the index liver biopsy and did not receive any
medication known to be associated with the development
of steatosis.
Medical records from these patients were traced and
the biopsies reviewed by experienced pathologists. A
total of 245 patients constituted the study group, 136
(56%) women and 109 men (44%). Women were in the
majority in the NAFLD group, 105/151 (70%) compared
to 46/151 (30%) men (p < 0.001). The proportion of men
was higher in the AFLD group, that is 67% (63/94)
whereas the proportion of women was 31/94 (33%).
Clinical and biochemical results
Clinical and biochemical data at the time of index liver
biopsy in the 245 patients of the two study groups
(Table 1). Information was available to calculate BMI in
56% of the total study cohort. No significant difference
Table 1 Clinical and biochemical data at the time of index liver biopsy
Baseline End of follow-up
NAFLD group AFLD group p-value NAFLD group AFLD group p-value
n = 151 n = 94 n = 151 n = 94
Gender (F/M) 105/46 31/63 <0.001
Female% 70% 33%
Mean (sd) or Median
(IQR)
Mean (sd) or Median
(IQR)
Age (years) 54 (14.7) 51 (13.5) NS
BMI (kg/m2) 29 (26–32) 29 (25–32) NS
AST (U/L) 47 (32–63) 76 (44–157) <0.001 48 (36; 28–46) 91 (46; 28–93) 0.05
ALT (U/L) 69 (44–102) 109 (58–198) 0.001 44 (36; 26–52) 67 (45; 27–75) 0.04
Bilirubin (μmol/L) 10 (7-15) 12 (9-21) 0.01 14 (9; 7–18) 49 (11; 9–21) NS
ALP (U/L) 197 (135–320) 179 (134–280) NS 196 (122; 87–157) 172 (119; 77–179) NS
Prothrombin time (sec) 13 (12-14) 14 (13-15) 0.02 16 (14; 13–17) 16 (14; 13–17) NS
Albumin (g/L) 40 (36–44) 39 (32–41) NS 37 (39; 33–42) 35 (37; 28–41) NS
Platelets (x109/L) 265 (92.9) 228 (83.3) 0.006 235 (238; 170–281) 219 (222; 152–265) NS
Random blood glucose
(mmol/L)
6 (5-7) 6 (5-7) NS 7 (6; 5–7) 7 (6; 5–7) NS
Cholesterol (mmol/L) 6 (5,6) 5 (5-7) NS 5 (5; 4–6) 5(5; 4–6) NS
Triglycerides (mmol/L) 2 (1-3) 2 (1-3) NS 2 (2; 1–2) 2 (2; 1–2) NS
MCV (fL) 90 (6.1) 95 (7.2) <0.001 90 (90; 87–94) 95 (95; 90–105) <0.001
Abbreviations: F female, M male, BMI body mass index, AST aspartate aminotransferase, ALT alanine transaminase, ALP alkaline phosphatase, MCV mean corpuscular
volume, NS not significant. Mean (sd) is shown for normally distributed variables, but median (IQR) for other variables. Obesity was defined as BMI ≥ 30 (kg/m).
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In the current context obesity was defined as BMI ≥ 30,
48/88 patients (55%) were obese in the NAFLD group
compared to 22/50 patients (44%) in the AFLD group
(NS). In the total cohort no significant difference was
observed between the genders in terms of obesity as 31/
76 (41%) of women were obese and 31/62 (50%) of the
men and no difference was seen in BMI when compar-
ing genders in the NAFLD and the AFLD group (data
not shown). A total of 74/88 (84%), 52 women vs. 22
men in the NAFLD group had a BMI > 25 compared to
38/50 (76%), 9 women vs. 29 men in the AFLD group
(NS).
The biochemical markers AST, ALT, bilirubin, pro-
thrombin time and MCV were higher and platelets
lower in the AFLD group compared to the NAFLD
group at the time of index liver biopsy whereas other
biochemical markers were similar in the two groups
(Table 1). At the end of follow-up, ALT, AST and MCV
were the only biochemical markers still significantly
higher in the AFLD group compared to the NAFLD
group (Table 1).
The clinical data on other diseases associated with the
metabolic syndrome at the time of index liver biopsy
and at the end of follow-up period in the two study
groups are shown in Table 2. The two groups had also
similar morbidity in terms of conditions associated withmetabolic syndrome both at baseline and at follow-up
(Table 2). Overall, 58 (62%) of the patients in the AFLD
group had undergone alcohol addiction therapy accord-
ing to computerized database of patients in the National
Centre of Addiction Medicine, whereas 2 (1%) in the
NAFLD group had undergone an addiction therapy, not
due to alcohol but due to abuse of sedatives and due to
a gambling addiction.
Histological end-points and development of cirrhosis
The histological characteristics in the index liver biopsy
are summarized in Table 3. According to the NAS score
overall 31/151 (21%) patients in the NAFLD group had
NASH compared to 35/94 (37%) with ASH in the AFLD
group (p = 0.007). In the nonalcoholic group 47 (31%)
patients had borderline NASH and 68 patients (45%) did
not have steatohepatitis. In the alcoholic group 35 (37%)
patients had borderline ASH (NS) and 22 (23%) did not
have ASH (NS). Patients in the NAFLD had less severe
lobular inflammation than the AFLD group (Table 3).
At the time of index liver biopsy 18 patients had cir-
rhosis, 6 patients in the NAFLD group and 12 in the
AFLD group, respectively. Overall, 11 patients devel-
oped cirrhosis during follow-up period, four patients in
the NAFLD group and seven patients in the AFLD
group. Thus, a total of 29 patients were diagnosed with
cirrhosis in the two groups, 10 (7%) patients in the
Table 2 Comorbid diseases at baseline and the end of follow-up period
Baseline End of follow-up
NAFLD AFLD p-value NAFLD AFLD p-value
n = 151 n = 94 n = 151 n = 94
n (%) n (%) n (%) n (%)
DM II 22 (15) 8 (9) NS 42 (28) 16 (17) NS
HTN 53 (35) 37 (39) NS 79 (52) 44 (47) NS
Hyperlipidemia 28 (19) 12 (13) NS 32 (21) 16 (17) NS
Cardio- and cerebrovascular disease 19 (13) 11 (11) NS 44 (29) 24 (26) NS
Abbreviations: NAFLD non-alcoholic fatty liver disease, AFLD alcoholic fatty liver disease, DM II diabetes mellitus type II, HTN hypertension.
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(p = 0.003).
Among patients developing cirrhosis in the follow-up
period the histological diagnosis at baseline was as fol-
low: one patient had no fibrosis (in the NAFLD group),
three patients had stage 1A fibrosis (all three in the
AFLD group), one patient had portal fibrosis (in the
NAFLD group) and six patients bridging fibrosis (four in
the AFLD group and two in the NAFLD group).
Liver-related complications
Patients developing liver cirrhosis and liver related com-
plications are demonstrated in Table 4. Among patients
diagnosed with cirrhosis a somewhat higher proportion
developed ascites in the AFLD group, 11/19 (58%) vs.
NAFLD, 3/10 (30%) (p = 0.004). Only one patient in the
AFLD group developed HCC but none of the NAFLD
patients developed HCC (Table 4). A significantly higher
number of patients in the AFLD group, 13/94 (14%)Table 3 Histological characteristics of NAFLD- and AFLD grou
NAFLD gr
n (%)
Steatosis
1 (5-33%) 77 (51)
2 + 3 (≥33%) 74 (49)
Lobular inflammation
0 + 1 (no foci or <2 foci/200x) 99 (66)
2 + 3 (2–4 foci or >4 foci/200x) 52 (34)
Ballooning
0 + 1 (none or few balloon cells) 139 (92)
2 (many cells) 12 (8)
Fibrosis
0 + 1 + 1A + 1B + 1C (none to mild fibrosis) 120 (79)
2 + 3 + 4 (moderate to severe) 31 (21)
NAS score
<3 68 (45)
3-4 47 (31)
≥5 31 (21)developed decompensated liver disease compared with
7/151 (5%) in the NAFLD group (Table 4). It should be
noted that baseline NAS score was different between
two groups with higher baseline NAS score in the AFLD
group (NAS score > 5: 37% vs 21%).
Survival and mortality
The median survival was 24.2 (range 0.2-26.1) years in
the NAFLD group and 19.5 (range 0.2-24.2) years in the
AFLD group (p = 0.0007). Median follow-up time for the
non-alcoholic group was 9.9 years (range 0.2-26 years)
and 9.2 years (0.2-25 years) for the alcoholic group.
There was no significant difference in overall survival
between the two study groups and no significant differ-
ence between genders (data not shown). Patients in the
AFLD group diagnosed with cirrhosis had a higher
death rate compared to the NAFLD group; 10 patients
(40%) in the AFLD group compared with 7 patients
(17%) in the NAFLD group (NS). Using Cox analysisp at index biopsy
oup AFLD group
p-value
n (%)
37 (39) NS
57 (61) NS
43 (46) 0.003
51 (54) 0.003
90 (96) NS
4 (4) NS
61 (65) 0.02
33 (35) 0.02
22 (23) 0.001
35 (37) NS
35 (37) 0.007
Table 4 Development of chronic liver disease such as
HCC, portal hypertension, varices and ascites
NAFLD group AFLD group
p-valuen = 151 n = 94
(%) (%)
Cirrhosis 10 (7) 19 (20) 0.003
Death 3 (2) 9 (10) 0.02
Ascites 3 (2) 11 (12) 0.004
Varices 3 (2) 6 (6) NS
Bleeding varices 1 (1) 1 (1) NS
Portal hypertension 3 (2) 2 (2) NS
HCC 0 (0) 1 (1) NS
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AFLD group compared to the NAFLD group after
adjusting for gender, calendar year of diagnosis and age
at diagnosis (HR 2.16, p = 0.009) (Figure 2). The hazard
ratio for women in the AFLD group was 1.19 compared
to the NAFDL group.
The survival for patients with moderate to severe fibrosis
was significantly worse than for patients with mild fibrosis
after adjusting for gender, calendar year of diagnosis and
age at diagnosis (HR 2.09, p = 0.01) (Figure 3).
A total of 67 patients died during the follow-up period;
41 women (61%) and 26 men (39%). Of these 12 (18%)
were liver related in both the NAFLD and AFLD group
(Table 5). The most common cause of death was due to
cardiovascular disease 28/67 (42%) followed by liver-related
disease 12/67 (18%) and malignancy 12/67 (18%) (Table 5).
7% of deaths were liver-related in the NAFLD group, no
man in the NAFLD group died of liver-related disease0.00
0.25
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Figure 2 Kaplan Meier survival plots showing survival from day of bir
NAFLD- and AFLD groups. The green line showing the NAFLD (non-alco
(alcoholic fatty liver disease) group.whereas three women had a liver-related death. In the
AFLD group the most common cause of death was liver-
related, 9/25 (36%) followed by cardiovascular disease in 8/
25 (32%) and malignancy among 6/25 (24%). The mean
liver-related death rate among the general population
during the study period was 0.1% of all deaths [13]. In the
AFLD group six men and three women died of liver-related
disease. Only one patient died from hepatocellular cancer
(HCC) in the total cohort and as mentioned above, from
the AFLD group.
The most common cause of death in the NAFLD group
was of cardiovascular disease 20/42 (48%), followed by
malignancy 6/42 (14%) and other chronic medical condi-
tions 4/42 (9.5%). A total of 12 patients (18%) died of
malignancy. In the AFLD group, 4 died of breast cancer
and one each of renal cancer, malignant brain tumor, colon
cancer, nasopharyngeal cancer and pancreas cancer. In the
NAFLD group, two died of breast cancer and one each of
prostate cancer, multiple myeloma, endometrial cancer
and one of small cell lung cancer.
Discussion
Few studies have determined the natural history of biopsy-
proven fatty liver disease and compared the long-term
prognosis of these two major groups of fatty liver disease
due to alcoholic and non-alcoholic fatty liver disease.
Our study has several methodological strengths. First,
all patients had biopsy proven fatty liver disease and
histology was re-evaluated based on validated scores. We
believe we have included the vast majority of patients with
biopsy-proven fatty liver disease in the whole population of
Iceland during this period as at least 95% of the population
lives in the catchment area of the National Universityp < 0.01
80 100
Age
121  98  61  29   4
 74  52  25   7   0
ber at risk
th after correcting for age, gender and year of diagnosis for the
holic fatty liver disease) group and the red line showing the AFLD
p = 0.01
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Figure 3 Kaplan Meier survival plots showing survival from day of birth after correcting for age, gender and year of diagnosis for the
none to mild fibrosis group (green line) and moderate to severe fibrosis group (red line).
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biopsy is also a weakness, especially when evaluating dis-
ease outcome. Previous studies have shown that NAFLD
patients diagnosed with liver biopsy have a worse prognosis
compared with patients diagnosed with ultrasonography.
Therefore, studying patients recruited from the pathology
registry involves a selection bias. It must be stressed that
the indications for the liver biopsy was not always clear,
although most cases were because of elevated liver function
tests and/or hepatomegaly or suspected alcoholic liver
disease, and this in turn can give a selection bias. Also the
indication for biopsy in NAFLD and AFLD may differ
between conditions and between practitioners and might
explain some of the differences in disease outcome.
The main limitation of the study was its retrospective
design and data was not systematically registrered and
was therefore sometimes missing or unavailable. In addition
the search for the code M-50080 (fatty liver) is limiting in
itself as the more serious steatosis with fibrosis and even
cirrhosis might be coded as something else than just fattyTable 5 Causes of death in NAFLD- and AFLD group
NAFLD group (n = 4
n (%)
Men Wo
Cardio- and cerebrovascular diseases 3 (15) 17
Liver-related diseases 0 (0) 3
Malignancy 2 (33) 4
Injury/poisoning 2 (67) 1
Other chronic medical condition 1 (25) 3
ARDS/pneumonia 0 (0) 2
Other 0 (0) 2liver. Since this was a retrospective study on liver biopsies it
is not possible to standardize the size of the needle biopsies.
Therefore the size is very variable and the range can be
considerable, but should be similar to the standards
observed in pathology departments in general. Samples less
than 2 mm in diameter would have been excluded from the
study, but no such samples came into the study.
The slides used for pathological estimation were the ori-
ginal slides and recuts or restaining of slides was not done
except for a few exceptional cases where the original slides
were unavailable or when a Masson-Trichrome stain had
not been performed originally. Occationally the colours of
the slides had faided somewhat. This however we do not
anticipate having significant effect on the results, espe-
cially since ballooning degeneration increases cell size and
this is not greatly affected by fading colours.
Another limitation is the small number of hard endpoints
with only four patients in the NAFLD group who devel-
oped cirrhosis over the follow-up period. There is also a
potential uncertainty in the non-histological diagnosis of2) AFLD group (n = 25) Total
n (%) n (%)
men Men Women
(85) 7 (88) 1 (12) 28 (42)
(100) 6 (67) 3 (33) 12 (18)
(67) 3 (50) 3 (50) 12 (18)
(33) 2 (100) 0 (0) 5 (7.5)
(75) 0 (0) 1 (100) 5 (7.5)
(100) 0 (0) 0 (0) 2 (3)
(100) 0 (0) 1 (100) 3 (4.5)
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reviewing the results.
The information on ASH should be interpreted with
caution as NAFLD activity score has to our knowledge
not yet been validated in AFLD, but we chose to use it for
comparison as the histolopathological development is
similar in the two conditions and there is no difference
morphologically between NAFLD and AFLD.
One of the main findings in this study was that patients
with fatty liver disease showed a markedly higher risk of
developing liver-related death compared to the general
population. Although significantly higher in the AFLD
group liver-related death in the NAFLD group was 7% of
all deaths. These findings are in contrast with liver-related
death rate in Iceland [13] which was a mean of 0.1% in the
general population during the study period. As in other
studies it is a challenge to classify patients into non-
alcoholic and alcoholic group. We tried to minimize the
misclassification by regrouping those without a known al-
cohol etiology if the patients were found to have an alco-
holic related diagnosis later as for instance alcohol
pancreatitis and alcohol dependence. In addition all pa-
tients were linked to the database for the National Centre
of Addiction Medicine in Iceland.
Liver-related morbidity and mortality
Our results show that patients with NAFLD had a rather
benign course in terms of liver-related morbidity and mor-
tality. Only 7% developed cirrhosis after a mean of 13 years
of follow-up which is similiar to what previous studies on
the prognosis of NAFLD have shown [6,7,14-17]. A higher
number of patients in the AFLD group developing cirrhosis
(20%) after approximately 12 years of follow-up, is also in
agreement with previous studies showing worse prognosis
in patients with AFLD than NAFLD [8,9,18]. These studies
have demonstrated that patients with alcoholic fatty liver
disease have worse prognosis of their liver disease than
patients with NAFLD [8,9,18]. In a study on prognosis and
life expectancy in chronic liver disease the five year survival
was 38% for the alcoholic group and 68% for the non-
alcoholic group but only 87% of the patient underwent liver
biopsy whereas the rest was diagnosed clinically or with
ultrasound [18]. In another study of 7000 patients dis-
charged with the diagnosis fatty liver the mortality was 5.4
fold amongst AFLD and 2.6 amongst NAFLD [19]. In the
current study we found that the overall survival was worse
in the AFLD group. Patients in the AFLD group had a
higher liver-related mortality, but patients in the NAFLD
group died more frequently from cardiovascular disease as
already demonstrated in previous studies [6,7,14,16].
In the AFLD group the most common cause of death
was liver-related (35%).
Other studies have shown that obesity in both NAFLD
and AFLD predispose to the development of fatty liver andchronic liver disease [19,20]. In Iceland, the prevalence of
liver cirrhosis due to alcohol is very low, only 3.3/100.000
inhabitants which was 4 times lower than in Sweden [21].
In the current study 45% of the patients in the NAFLD
group had a BMI ≥30 and somewhat surprisingly there was
no significant difference in BMI between the NAFLD group
and the AFLD group. The fact that patients with AFLD did
not differ with respect to BMI and incidence of metabolic
syndrome-related diseases might reflect a mixed AFLD/
NAFLD etiology in the alcoholic group. In the Dionysos
study, obesity among heavy drinkers, increased the risk for
steatosis by twofold [19]. Moreover, no significant differ-
ences were evident concerning conditions associated with
metabolic syndrome neither at baseline nor at follow-up,
but we had expected a higher portion of diseases associated
with metabolic syndrome in the NAFLD group. In a study
from Denmark, a significantly higher BMI was seen in
NAFLD than in AFLD patients. However, this might at
least partly reflect the fact that their patients were recruited
from an obesity research project [8] whereas our patients
were unselected patients undergoing a liver biopsy.
In the current study women were in the majority in the
NAFLD group but the high proportion of women with
fatty liver compared to men may reflect a higher disease
burden in women. A recent study from the US also found
a higher proportion of women in the NAFLD group [22]
which is in line with our results. A significantly higher
prevalence of cirrhosis in female AFLD patients was
observed in a Danish study and time to cirrhosis was asso-
ciated with female gender [10]. Population based studies
have shown increased risk of women developing alcohol-
induced cirrhosis [23-26].
Progression of NAFLD has been found to be slow and
seems to depend a great deal on the initial fibrosis stage
[8,14]. Patients with simple fatty liver at baseline seem to
have a good prognosis in terms of liver disease. In a Danish
study of 109 patients diagnosed with pure non-alcoholic
simple steatosis (without inflammation or significant
fibrosis) only one of the patients developed cirrhosis [8]. In
the current study more severe lobular inflammation was
found in the AFLD group compared to the NAFLD group
and a significantly higher number of patients in the AFLD
group had steatohepatitis compared to the NAFLD group.
In the total study cohort patients with more severe
fibrosis at baseline showed a worse overall survival than
patients with none or mild fibrosis at baseline. Based on
this we were able to show an association in the total study
cohort between the stage of fibrosis and the prognosis.
However more NAFLD than AFLD patients had mild or
no fibrosis at baseline. This is in agreement with results
from a recent study showing that advanced fibrosis in the
index liver biopsy was the most important predictor of the
prognosis in these patients [27]. A recent Danish study
showed that the cirrhosis risk was more than twice as high
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A Swedish cohort study of patients with biopsy-proven
NAFLD and elevated liver tests showed that they had a
similar survival compared to the Swedish population [7].
Interestingly the risk of death was increased in patients
with non-alcoholic steatohepatitis [7].
A study from Minnesota, identified 420 patients with
NAFLD by imaging or liver biopsy found liver-related com-
plications to be the third most common cause of death
among NAFLD patients [6]. This is similar to our results
showing liver-related to be the third most common cause
of death amongst the NAFLD group. However in the AFLD
group liver-related death was the leading cause of death,
followed by cardiovascular diseases and malignancy which
is in accordance to a previous study where hepatobiliary
disease was the leading cause of death in the AFLD [9].
In the current study, no patient in the NAFLD group
died of hepatocellular carcinoma and only one patient in
the AFLD group. The absence of HCC among the
NAFLD group differs from previous cohort studies
showing that 3/129 (2%) [7] and 2/420 (0.5%) [6] of
NAFLD patients developed HCC [7]. A reasonable ex-
planation for this difference in our study could be that
our patients had in general mild changes in the liver bi-
opsy at baseline. It is also conceivable that a longer
follow-up time would probably lead to patients with
HCC.
Cardiovascular disease
In agreement with many previous studies a markedly higher
proportion of our women in the NAFLD group died of
cardiovascular disease compared to women in the AFLD
group, 17 patients vs. one patient respectively. A previous
study [10] showed that cardiovascular disease was the
leading cause of death in the AFLD group (men and
women toghether), which is at odd with our results. In the
current study the leading cause of death in the AFLD group
was liver related. We can not find a plausible explanation
for this difference, although it has been shown that diagno-
ses on death certificates can underestimate liver-related
mortality [28] which might have been the case in the
Danish study [10].
The most common cause of death in the NAFLD group
was from cardiovascular disease, followed by malignancy
which is in agreement with findings of other cohort studies
(6, 7, 14, 16,). One study found 34% increased risk of
cardiovascular mortality among NAFLD patients com-
pared to the general Minnesota population over a 7.6 year
follow-up [6].
Conclusion
In conclusion a higher proportion of patients with AFLD
developed liver cirrhosis and had liver-related deathcompared to patients with NAFLD in this population based
setting and had also more severe histological changes in the
liver biopsy at baseline. Patients in the AFLD group showed
a significantly worse survival compared to patients in the
NAFLD group. Patients with more severe fibrosis at base-
line showed a worse survival than patients with none or
mild fibrosis at baseline. Patients with fatty liver disease
showed a markedly higher risk of developing liver-related
death compared to the general population.
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